spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ecallantide 

 HSMN NewsFeed - 2 Nov 2015
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2013
Dyax Corp. and Novellus Biopharma AG Announce Partnership to Develop and Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Aug 2012
Dyax Corp. Creates COO Position and Expands Executive Roles
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2011
Dyax and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Aug 2010
Data from First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2009
Cubist Pharmaceuticals to Acquire Calixa Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Dec 2009
Trial Date Set for CUBICIN(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 7 Dec 2009
FDA Grants First Approval for a Product Derived from Pichia pastoris
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Dec 2009
Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Dec 2008
Cubist Names Santosh J. Vetticaden as SVP, Clinical Development and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2008
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2007
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Biopharmaceuticals Surgery Cardiology
 HSMN NewsFeed - 17 Apr 2007
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Biopharmacetuicals
 HSMN NewsFeed - 12 Apr 2007
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Positive Final Results from EDEMA2 Trial with DX-88 for the Treatment of Hereditary Angioedema Presented at ACAAI Meeting
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
ecallantide
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.